Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Insider Sells $441,795.96 in Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider James Woodruff Lillie sold 15,801 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $27.96, for a total transaction of $441,795.96. Following the transaction, the insider owned 279,356 shares in the company, valued at approximately $7,810,793.76. This represents a 5.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Woodruff Lillie also recently made the following trade(s):

• On Wednesday, May 6th, James Woodruff Lillie sold 24,811 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.76, for a total transaction of $713,564.36.
• On Tuesday, May 5th, James Woodruff Lillie sold 11,095 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.20, for a total transaction of $312,879.00.

Maplight Therapeutics Stock Performance

MPLT stock opened at $27.40 on Friday. Maplight Therapeutics, Inc. has a 1 year low of $12.24 and a 1 year high of $33.28. The firm has a fifty day simple moving average of $22.83. The firm has a market cap of $1.17 billion and a price-to-earnings ratio of -0.69.

Maplight Therapeutics (NASDAQ:MPLT) last released its quarterly earnings data on Thursday, March 26th. The company reported ($2.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($1.42). Sell-side analysts anticipate that Maplight Therapeutics, Inc. will post -3.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on MPLT. HC Wainwright began coverage on shares of Maplight Therapeutics in a research note on Monday. They issued a “buy” rating and a $45.00 price objective for the company. Canaccord Genuity Group began coverage on shares of Maplight Therapeutics in a research note on Thursday, March 19th. They issued a “buy” rating and a $35.00 price objective for the company. TD Cowen began coverage on shares of Maplight Therapeutics in a research note on Tuesday, April 7th. They issued a “buy” rating for the company. Wall Street Zen lowered shares of Maplight Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, Weiss Ratings began coverage on shares of Maplight Therapeutics in a research note on Thursday, January 22nd. They issued a “sell (e)” rating for the company. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.43.

Trending Headlines about Maplight Therapeutics

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: MapLight Therapeutics announced that management will participate in upcoming investor conferences, which can help keep the company visible to potential investors and may provide a near-term catalyst. MapLight Therapeutics to Participate in Upcoming Investor Conferences
• Positive Sentiment: Needham reiterated a Buy rating on MPLT, reinforcing Wall Street support for the stock and helping offset some of the recent negative sentiment. Needham Reaffirms Buy Rating
• Positive Sentiment: Recent analyst coverage elsewhere in the tape remained constructive, including Buy ratings and higher price targets, which supports the longer-term bullish case for MapLight Therapeutics. Analyst coverage summary
• Neutral Sentiment: The company’s recent earnings history remains mixed, with a prior quarterly loss wider than expected; this is still part of the backdrop but not the main driver of today’s move. MPLT earnings summary
• Negative Sentiment: Multiple insiders, including CEO Christopher Kroeger, CFO Vishwas Setia, and insiders James Woodruff Lillie and Erin Pennock Foff, sold shares over May 4–6. Although the sales were made under pre-arranged Rule 10b5-1 plans, the cluster of transactions can weigh on sentiment and suggest near-term selling pressure. CEO Form 4 filing
• Negative Sentiment: The repeated insider sales may be contributing to the stock’s decline today, as investors often view sustained insider selling as a cautionary signal even when it is pre-planned. Insider sale filing

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of MPLT. Fcpm Iii Services B.V. acquired a new position in Maplight Therapeutics during the 4th quarter worth $56,672,000. T. Rowe Price Investment Management Inc. acquired a new position in Maplight Therapeutics during the 4th quarter worth $49,154,000. Goldman Sachs Group Inc. acquired a new position in Maplight Therapeutics during the 4th quarter worth $34,026,000. Nan Fung Group Holdings Ltd acquired a new position in Maplight Therapeutics during the 4th quarter worth $17,060,000. Finally, 5AM Venture Management LLC acquired a new position in Maplight Therapeutics during the 4th quarter worth $16,687,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.